Clinical Trial Update: EGFR Monoclonal Antibody for Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating an EGFR-targeting monoclonal antibody for advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Shanghai Changzheng Hospital | Conditions: Gastric Cancer, Cetuximab | Phase 2 | Status: UNKNOWN